Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $10.50 for the company and are expecting that the company will post ($0.32) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aralez Pharmaceuticals an industry rank of 112 out of 265 based on the ratings given to related companies.
ARLZ has been the subject of a number of research analyst reports. Chardan Capital restated a “buy” rating and issued a $10.00 target price on shares of Aralez Pharmaceuticals in a research note on Friday, September 16th. Guggenheim restated a “positive” rating and issued a $12.00 target price on shares of Aralez Pharmaceuticals in a research note on Tuesday, October 4th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.12 on Friday. The firm has a 50-day moving average price of $5.29 and a 200-day moving average price of $4.20. The company’s market cap is $334.03 million. Aralez Pharmaceuticals has a 52 week low of $3.10 and a 52 week high of $8.59.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The business earned $12.60 million during the quarter, compared to the consensus estimate of $9.70 million. Aralez Pharmaceuticals had a negative return on equity of 73.21% and a negative net margin of 224.35%. The company’s quarterly revenue was up 142.3% on a year-over-year basis. Equities research analysts anticipate that Aralez Pharmaceuticals will post ($1.06) EPS for the current fiscal year.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of Aralez Pharmaceuticals stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the completion of the transaction, the director now owns 669,094 shares in the company, valued at $3,894,127.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.77% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can bought a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $100,000. Advisor Group Inc. bought a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $118,000. Knott David M bought a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $124,000. Alpine Partners VI LLC bought a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $133,000. Finally, LMR Partners LLP bought a new position in shares of Aralez Pharmaceuticals during the second quarter worth about $145,000. Institutional investors and hedge funds own 49.63% of the company’s stock.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.